Corbus Pharmaceuticals Holdings (CRBP) Current Deferred Revenue (2015 - 2020)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Current Deferred Revenue of $270530.0 for Q2 2020, down 89.1% year-over-year from $2.5 million in Q3 2019, and down 89.1% quarter-over-quarter from $2.5 million in Q2 2019.
Corbus Pharmaceuticals Holdings (CRBP) Current Deferred Revenue (2015 - 2020) Analysis & Trends
Corbus Pharmaceuticals Holdings' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $270530.0 for Q2 2020.
- In Q2 2020, Current Deferred Revenue fell 89.1% year-over-year to $270530.0; the TTM figure through Jun 2020 stood at $270530.0 (down 89.1% YoY), while the FY2018 annual figure was $1.5 million, changed N/A from the prior year.
- Current Deferred Revenue for Q2 2020 stood at $270530.0, down from $2.5 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $27.0 million in Q1 2019, with the low at $270530.0 in Q2 2020.
- The 5-year median for Current Deferred Revenue is $1.5 million (2016), against an average of $3.8 million.
- The sharpest annual moves came in 2018 and 2020: Current Deferred Revenue surged 1412.16% in 2018, then sank 89.1% in 2020.
- Corbus Pharmaceuticals Holdings' Current Deferred Revenue stood at $1.9 million in 2016, then plunged by 84.73% to $296311.0 in 2017, then soared by 393.57% to $1.5 million in 2018, then jumped by 69.73% to $2.5 million in 2019, then tumbled by 89.1% to $270530.0 in 2020.
- Business Quant data shows CRBP's Current Deferred Revenue at $270530.0 in Q2 2020, $2.5 million in Q2 2019, and $27.0 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 270,530.00 |
| Jun 30, 2019 | 2.48 Mn |
| Mar 31, 2019 | 27.00 Mn |
| Dec 31, 2018 | 1.46 Mn |
| Sep 30, 2018 | 3.39 Mn |
| Jun 30, 2018 | 4.48 Mn |
| Jun 30, 2017 | 296,311.00 |
| Mar 31, 2017 | 646,498.00 |
| Dec 31, 2016 | 1.94 Mn |
| Sep 30, 2016 | 1.32 Mn |
| Jun 30, 2016 | 1.06 Mn |
| Mar 31, 2016 | 1.46 Mn |
| Dec 31, 2015 | 1.85 Mn |
| Sep 30, 2015 | 681,816.00 |
| Jun 30, 2015 | 681,616.00 |